The Wennberg International Collaborative, London, 2-4 September 2015

Size: px
Start display at page:

Download "The Wennberg International Collaborative, London, 2-4 September 2015"

Transcription

1 The Wennberg International Collaborative, London, 2-4 September 2015 Diagnosis and Treatment of Dementia Variation in ambulatory care for patients in Germany with special reference to non-institutionalized patients (work in progress; unpublished parts not to be cited) Dr. Dominik von Stillfried, Dr. Mandy Schulz et al Zentralinstitut für die Kassenärztliche Versorgung in Deutschland

2 Objective to explore present state of care for patients with dementia who live at home (fast growing patient group) to identify the potential for systematic improvement of care by analysing deviations from guideline recommendation (diagnosis, medication) describing regional patterns where to act? analysing utilization and behavioral patterns, in particular using network analysis to compare patient care by type of main provider rationale: with whom do we need to talk about what? see published reports concerning diagnostic process / medication for dementia patients in Germany on SEITE 2

3 Data nationwide claims data bases containing 100% of all statutorily insured patients (~ 70 million) 100% of physician claims (~ 550 million cases p.a.), i.e. of GPs and office-based specialists (~ practices) & ER claims by hospitals for patients not admitted to inpatient care 100% of filled prescriptions (~ 600 million prescriptions p.a.) data selected for patients > 60 years, confirmed dementia dx (at least in two quarters of a year) as documented by GP and/or Neurologist/Psychiatrists (NP) only (analysis of diagnostic process) and by GP and/or all specialties resp. (analysis of medication), years 2009, 2010, 2011 join of selected dx with prescription data (anti-dementive, anti-psychotic, hypnotic/sedative, anti-depressant drugs) not available: hospital claims for inpatient care or ambulatory surgery claims by logotherapist, ergotherapists etc. SEITE 3

4 Selected Dementia-Diagnoses, Prevalenc/Incidence 1. Alzheimer s dementia (AD) F00.x, G30.x 2. Vascular dementia (VD) F01.x 3. Other dementia with specific etiology F02.0, F02.3, G31.0, G Other dementia with non-specific etiology F03, G31.1, G Combinations of 1-4 Definitions according to Kaduskiewicz H et al 2013 Prevalent patients: n= ( F, M) in 2009 Incident patients: n= ( F, M) without dx in 2008 (for analysis of diagnostic process) N.B. for analysis of medication a slightly different dataset was used which did not allow to focus on diagnoses documented by GP and NP or to differentiate non-institutionalized patients (prevalent patients: 2009: n = (Hamburg excluded due to missing data), 2010: n = ; 2011: n = ) SEITE 4

5 Prevalence/Incidence (Rates) including institutionalized patients SEITE 5

6 Prevalence/Incidence (Regional Distribution) including institutionalized patients SEITE 6

7 Who sees whom? incident non-institutionalized patients Incident patients GP only specialist only GP+specialist group practice Alzheimer 7.7% 27.7% 9.2% 12.3% Vascular 14.1% 21.9% 2.8% 9.3% other specific 1.0% 5.6% 0.3% 2.1% other non- specific 66.9% 29.9% 16.6% 33.8% combinations 10.3% 14.9% 71.1% 42.5% total 100% 100% 100% 100% n=133,644 patients, year 2009 variation in coding between GP/specialists confounds potential variation in utilization patterns SEITE 7

8 Diagnostic Process incident non-institutionalized patients Incident patients all GP only specialist only GP+specialist group practice m f m f m f m f m f lab tests neuropsychiatric tests imaging n=133,644 patients, year 2009 Diagnostic intensity varies with utilization pattern: - patients seen by GP only may receive insufficient diagnostic testing - patients seen by both GP and specialist are most intensely diagnosed - there is room for increased neuropsychiatric testing Irrespective of utilization there is a consistent gender pattern (f < m) SEITE 8

9 Diagnostic Process moderate regional variation suggesting partially substitutive effects Percent of incident patients diagnosed with lab tests neuropsychiatric tests imaging SEITE 9

10 Medication: underuse of antidementives/overuse of antipsychotics? N.B. m/f ratio reversed, distinctive regional pattern percent of medication patients antidementive antipsychotic hypnotic/sedative antidepressant m f type of dementia Alzheimer vascular other specific other non- specific combination utilization GP only specialist only GP+specialist other region large city metropolitan rural near city rural unknown total N=1,014,710 prevalent patients in 2011 SEITE 10

11 Network analysis network nucleus: patients have been attributed to primary care physician who delivered most services to this patient irrespective of diagnoses all other GPs or specialists contacted by the patient form a virtual provider network with this primary care physician networks with very few patients (N <10) were exluded dementia patients: all prevalent patients in 2011 attributed to a network (N = 838,125) dementia networks : problems of small numbers and uneven distribution of dementia patients SEITE 11

12 prevalent dementia patients in virtual provider networks N=838,125 (2011) 120 Number of dementia patients per virtual provider network % of virtual provider networks 90% of virtual provider networks 99% of virtual provider networks Number of prevalent dementia patients Up to 19 Up to 50 Up to 103 MIN 1 MAX % 10% 20% 30% 40% 50% 60% 70% 80% 90% 99% Frequency (percentiles) * Networks with 10 patients or less were SEITE 12 Wennberg International Collaborative excluded, London, 2-4 September 2015

13 Number of incident* dementia patients in virtual provider networks N=233,354 (2011) *without dementia dx in 2009 and in 2010 Number of incident dementia patients Number of dementia patients per virtual provider network 50% of virtual provider networks 90% of virtual provider networks 99% of virtual provider networks Up to 6 Up to 14 Up to 30 MIN 1 MAX 217 networks without incident dementia patients have significantly fewer prevalent dementia patients frequency (percentiles) SEITE 13

14 Regional Variation in the distribution of network populations size marked differences between regions but no discernable pattern according to area type or provider structure SEITE 14

15 Diagnostic approach according to type of network percent of patients receiving neuropsychiatric testing type of network GP Neurolog ist Psychiatr ist Group practice total CT MRT <10 incident dementia patients incident dementia patients 50% percentile of networks 90% percentile of networks 18,10% 6,60% 5,10% 9,60% 39,40% 9,60% 8,10% 22,30% 4,80% 4,30% 7,90% 39,40% 9,80% 7,10% >20 incident dementia patients 99% percentile of networks 48,30% 2,00% 2,20% 5,00% 57,50% 9,30% 6,30% incident dementia patients without patients in long term care facilities, N= (2011) role of GP and importance of neuropsychiatric testing increase with no. of dementia patients SEITE 15

16 Prescription rates vary according to population size of virtual network (rates fall as population size increases) prevalent patients large (>100 prevalent size of functional population medium ( prevalent small (<50 prevalent total Anti-dementive drugs 16.9% 21.4% 26.5% 24.7% Antipsychotics 34.0% 36.4% 35.6% 35.7% Hypnotics/sedatives 9.1% 9.3% 9.3% 9.3% Antidepressants 28.5% 29.7% 29.5% 29.5% n=838,125, including institutionalized patients (2011) size of functional population incident patients large (>30 incident medium (14-30 incident small (<14 incident total Anti-dementia drugs 13.6% 21.8% 26.4% 24.4% Antipsychotics 27.5% 33.1% 32.2% 32.5% Hypnotics/sedatives 9.4% 9.8% 9.6% 9.7% Antidepressants 28.3% 31.0% 30.5% 30.5% n=233,354, including institutionalized patients (2011) SEITE 16

17 Taking a look at the networks - how important are dementia patients within the network population? networks share of dementia patients (in all patients of the network) large (>100 prevalent size of functional population medium ( prevalent small (<50 prevalent total high (share >10%) medium (share 4-10%) 223 1,903 3,599 5,725 low (share <4%) 30 1,045 26,979 28,054 total 370 3,040 30,635 34,045 no of virtual networks: n=34,045 (2011) < 1 percent of provider networks (266) had a high share of dementia patients, almost half of them had > 100 dementia patients per year the vast majority (79%) of networks had a low share and a low number of dementia patients SEITE 17

18 And how important are networks with a focus on dementia? networks share of dementia patients (relative to all patients of the network) large (>100 prevalent size of functional population medium ( prevalent small (<50 prevalent total high (share >10%) 19,275 7,057 1,659 27,991 medium (share 4-10%) 28, , , ,919 low (share <4%) 3,407 65, , ,215 total 51, , , ,125 no. of prevalent dementia patients, n=838,125 (2011) virtual provider networks with a focus (high share and a high number of dementia patients) treat only 2.3% of all dementia patients, whereas > 50% of dementia patients were treated by networks with low share and low size. SEITE 18

19 And how important are networks with a focus on dementia? Prescription rates of anti-dementia drugs share of dementia patients (relative to all patients of the network) large (>100 prevalent size of functional population medium ( prevalent small (<50 prevalent total high (share >10%) 14.9% 17.1% 18.0% 15.7% medium (share 4-10%) 17.6% 20.5% 22.9% 21.2% low (share <4%) 22.0% 23.7% 27.4% 26.9% total 16.9% 21.4% 26.9% 24.4% no. of prevalent dementia patients, n=838,125 (2011) Networks with a focus on dementia show the lowest prescription rate of antidementia drugs ( guideline recommendation) Are these opinion leaders? Do they favor other treatment options? Do they collect specific patients (e.g. rare/serious cases, patients in long term care facilities?) What constitutes the dependence on patient population size? SEITE 19

20 And how important are networks with a focus on dementia? Prescription rates of anti-psychotic drugs share of dementia patients (relative to all patients of the network) large (>100 prevalent size of functional population medium ( prevalent small (<50 prevalent total high (share >10%) 31.5% 34.2% 34.5% 32.3% medium (share 4-10%) 35.3% 35.6% 35.0% 35.3% low (share <4%) 37.2% 38.3% 35.7% 36.0% total 34.0% 36.4% 35.6% 35.7% no of prevalent dementia patients, n=838,125 (2011) Networks with a focus on dementia show the lowest prescription rate of antipsychotic drugs, there is an effect of size and focus, but the difference is small (similar for hypnotics/sedatives and anti-depressants) What prevents a greater reduction in prescribing rates? What could other networks learn from them? SEITE 20

21 Conclusions There is room for improvement in the diagnostic process of dementia patients - in general, more cooperation between GP and specialists would be welcomed Prescription of anti-psychotics seems high given potentially dangerous effects. Prescription of anti-dementia drugs is low compared to guideline recommendations. This pattern is observed both in prevalent and in incident dementia patients. Prescription rates of anti-dementia drugs are affected by characteristics of virtual provider networks (size of functional population and share of but a focus on dementia patients leads to greater deviation from recommendations There is no clear evidence of substition with other drugs or other kinds of treatment, however, prescription of antipsychotics increases with decreasing share of dementia patients Before designing intervention: reasons for observed pattern need to be explored by communication with various network representatives SEITE 21

22 Vielen Dank für Ihre Aufmerksamkeit Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland Herbert-Lewin-Platz Berlin Tel Fax zi@zi.de SEITE 22

Longitudinal regional analyses of an1bio1c consump1on in statutory health care insured pa1ents in Germany since 2008

Longitudinal regional analyses of an1bio1c consump1on in statutory health care insured pa1ents in Germany since 2008 Longitudinal regional analyses of an1bio1c consump1on in statutory health care insured pa1ents in Germany since 2008 Jörg Bätzing- Feigenbaum - Maike Schulz - Mandy Schulz - Jana Gisbert Miralles - Dominik

More information

COGNOS. Care for people with Cognitive dysfunction A National Observational Study. Professor Dr Jan De Lepeleire COGNOS members

COGNOS. Care for people with Cognitive dysfunction A National Observational Study. Professor Dr Jan De Lepeleire COGNOS members COGNOS Care for people with Cognitive dysfunction A National Observational Study Professor Dr Jan De Lepeleire COGNOS members Luxembourg Alzheimer Europe 2010 The Careplan in Belgium Requirements for reimbursement

More information

Prevalence of Mental Illness

Prevalence of Mental Illness Section 1 Prevalence of Mental Illness The prevalence of mental health problems or mental illness appears to be quite stable over time. Full epidemiological surveys of prevalence, reported using complex

More information

Pediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form

Pediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form Pediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form Please fax form to 617.673.0988 or mail to Tufts Health Plan, 705 Mount Auburn Street, Watertown, MA 02472, Attn:

More information

CHCS. Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia. Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES

CHCS. Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia. Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES CHCS Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia December 2010 Cynthia Boyd, MD, MPH* Bruce Leff, MD* Carlos

More information

MEDICATIONS PRESCRIPTION AT HOSPITAL DISCHARGE IN PATIENTS WITH VALIDATED DIAGNOSIS OF DEMENTIA. Federica Edith Pisa University Hospital Udine

MEDICATIONS PRESCRIPTION AT HOSPITAL DISCHARGE IN PATIENTS WITH VALIDATED DIAGNOSIS OF DEMENTIA. Federica Edith Pisa University Hospital Udine MEDICATIONS PRESCRIPTION AT HOSPITAL DISCHARGE IN PATIENTS WITH VALIDATED DIAGNOSIS OF DEMENTIA Federica Edith Pisa University Hospital Udine BACKGROUND Polypharmacy and psychotropic medication use are

More information

Psychotropic Medication. Including Role of Gradual Dose Reductions

Psychotropic Medication. Including Role of Gradual Dose Reductions Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which

More information

ffice for the Study of Aging University of South Carolina, USA Presented at REVES 2005, Beijing, China

ffice for the Study of Aging University of South Carolina, USA Presented at REVES 2005, Beijing, China Life Expectancy for Individuals with Alzheimer s Disease or Related Disorders: Evidence of a Black / White Mortality Crossover James N. Laditka, Sarah B. Laditka With Carol B. Cornman Candace N. Porter,

More information

Cost of Mental Health Care

Cost of Mental Health Care Section 4 Cost of Mental Health Care Per capita mental health spending for Americans with a mental health diagnosis has increased among children, peaking in. For adults, the spending has been more stable.

More information

Medi Cal Managed Care. Melissa Lamer, PharmD, BCPP July 31 st, 2014

Medi Cal Managed Care. Melissa Lamer, PharmD, BCPP July 31 st, 2014 Pharmacy Benefit Carve Outs in Medi Cal Managed Care Melissa Lamer, PharmD, BCPP July 31 st, 2014 2 The Behavioral Health Carve Out Services Carved Out to the County Starting 1/1/2014 Medi Cal plans now

More information

Developing mental health care in Europe - what can Germany learn from Member States and how can Member States profit from German experience?

Developing mental health care in Europe - what can Germany learn from Member States and how can Member States profit from German experience? Developing mental health care in Europe - what can Germany learn from Member States and how can Member States profit from German experience? Prof. Dr. Rainer Richter De-medicalising primary mental health

More information

EKIV Newsletter 3/2010

EKIV Newsletter 3/2010 Evaluation of Gesundes Kinzigtal Integrated Care EKIV Newsletter 3/2010 edited by Evaluations-Koordinierungsstelle Integrierte Versorgung (EKIV) Dept. of Medical Sociology Albert-Ludwigs-University Freiburg

More information

Behavioral Health Evaluation

Behavioral Health Evaluation This document is intended to serve as a template for a behavioral health committee meeting in an extended care facility. The State Operations Manual (SOM), Appendix PP - "Guidance to Surveyors for Long

More information

Value of Hospice Benefit to Medicaid Programs

Value of Hospice Benefit to Medicaid Programs One Pennsylvania Plaza, 38 th Floor New York, NY 10119 Tel 212-279-7166 Fax 212-629-5657 www.milliman.com Value of Hospice Benefit May 2, 2003 Milliman USA, Inc. New York, NY Kate Fitch, RN, MEd, MA Bruce

More information

Renewing priority for dementia: Where do we stand?

Renewing priority for dementia: Where do we stand? Policy brief Renewing priority for dementia: Where do we stand? Renewing priority for dementia: Where do we stand? Contents Overview 03 Putting dementia higher on the agenda 04 Diagnosing and identifying

More information

Appendix 1. Cognitive Impairment and Dementia Service Elm Lodge 4a Marley Close Greenford Middlesex UB6 9UG

Appendix 1. Cognitive Impairment and Dementia Service Elm Lodge 4a Marley Close Greenford Middlesex UB6 9UG Appendix 1 Mr Dwight McKenzie Scrutiny Review Officer Legal and Democratic Services Ealing Council Perceval House 14 16 Uxbridge Road Ealing London W5 2HL Cognitive Impairment and Dementia Service Elm

More information

Use of anti-psychotic medication in care homes Response from the Royal Pharmaceutical Society in Wales

Use of anti-psychotic medication in care homes Response from the Royal Pharmaceutical Society in Wales Use of anti-psychotic medication in care homes Response from the Royal Pharmaceutical Society in Wales About us The Royal Pharmaceutical Society (RPS) is the professional body for pharmacists in Great

More information

9/11/2012. Clare I. Hays, MD, CMD

9/11/2012. Clare I. Hays, MD, CMD Clare I. Hays, MD, CMD Review regulatory background for current CMS emphasis on antipsychotics Understand the risks and (limited) benefits of antipsychotic medications Review non-pharmacologic management

More information

Depression in Chronic Physical Health Problems FULL GUIDELINE 1

Depression in Chronic Physical Health Problems FULL GUIDELINE 1 O Connor 2005 U.S.A. Sertraline Placebo Study design data source Patients who were hospitalised for acute coronary syndromes and who met the APA s DSMIV criteria for major depressive disorder (MDD). :

More information

RADIOLOGY VERSION 5. Retrospective data in full ACIR

RADIOLOGY VERSION 5. Retrospective data in full ACIR RADIOLOGY VERSION 5 Retrospective data in full ACIR 2008-2015 Contents Radiology, version 5 1 Report availability... 1 1.1 Emergency department / critical care unit plain radiography reports (L) 1 1.2

More information

NCI Data Brief. ISSUE 6 December 2012

NCI Data Brief. ISSUE 6 December 2012 NCI Data Brief ISSUE 6 December 2012 What does NCI tell us about adults with intellectual and developmental disabilities who are taking prescribed medications for anxiety, behavior challenges, mood disorders

More information

Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian

Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian German Center for Neurodegenerative Diseases (DZNE), site

More information

SYNOPSIS. Trial No.: RIS-USA-70 Clinical phase: III. JRF, Clinical Research Report RIS-USA-70, 16 October, 1998 N Trial period: Start: 20 Nov 95

SYNOPSIS. Trial No.: RIS-USA-70 Clinical phase: III. JRF, Clinical Research Report RIS-USA-70, 16 October, 1998 N Trial period: Start: 20 Nov 95 SYNOPSIS Trial identification and protocol summary Company: Janssen Research Foundation Finished product: RISPERDAL Active ingredient: Risperidone (R064,766) Title: An open-label, long-term study of risperidone

More information

Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia

Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia Aine Leen, Kieran Walsh, David O Sullivan, Denis O Mahony, Stephen Byrne, Margaret Bermingham Pharmaceutical Care Research Group,

More information

Aspartate Aminotransferase Testing in Community-Based Laboratories: An Expert Consultation

Aspartate Aminotransferase Testing in Community-Based Laboratories: An Expert Consultation Aspartate Aminotransferase Testing in Community-Based Laboratories: An Expert Consultation B McCurdy June 2013 Aspartate Aminotransferase Testing in Community-Based Laboratories. June 2013; pp. 1 11. Suggested

More information

ICRU Report 91 Was ist neu, was ändert sich?

ICRU Report 91 Was ist neu, was ändert sich? DEGRO Stereotaxie Meeting 21.10.2017 ICRU Report 91 Was ist neu, was ändert sich? Lotte Wilke, Stephanie Tanadini-Lang, Matthias Guckenberger Klinik für Radio-Onkologie, Universitätsspital Zürich History

More information

Nuplazid. Nuplazid (pimavanserin) Description

Nuplazid. Nuplazid (pimavanserin) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.03 Subject: Nuplazid Page: 1 of 4 Last Review Date: June 22, 2018 Nuplazid Description Nuplazid (pimavanserin)

More information

Dementia Strategy MICB4336

Dementia Strategy MICB4336 Dementia Strategy 2013-2018 MICB4336 Executive summary The purpose of this document is to set out South Tees Hospitals Foundation Trust s five year strategy for improving care and experience for people

More information

Palliative Care and End of Life Care

Palliative Care and End of Life Care Palliative Care and End of Life Care Relevant Data and References Victorian Population 1 Total Victorian Population as at June 2016 was 6.1 million (6,179,249) Victorian 60 plus population as at June 2016

More information

Identifying Adult Mental Disorders with Existing Data Sources

Identifying Adult Mental Disorders with Existing Data Sources Identifying Adult Mental Disorders with Existing Data Sources Mark Olfson, M.D., M.P.H. New York State Psychiatric Institute Columbia University New York, New York Everything that can be counted does not

More information

RURAL HEALTH AND ITS INFLUENCE ON THE GP PERSPECTIVE OF DEMENTIA

RURAL HEALTH AND ITS INFLUENCE ON THE GP PERSPECTIVE OF DEMENTIA RURAL HEALTH AND ITS INFLUENCE ON THE GP PERSPECTIVE OF DEMENTIA 14 TH NATIONAL RURAL HEALTH CONFERENCE APRIL 2017 ANGE CROMBIE, DIRECTOR RESEARCH & DEVELOPMENT Background Australia, like the rest of the

More information

Dr Belinda McCall Consultant Geriatrician

Dr Belinda McCall Consultant Geriatrician Dr Belinda McCall Consultant Geriatrician Overview Background to our service Project Initial service provision Further developments Benefits of a geriatrician Questions Background National Dementia Strategy

More information

Prescribing medications for people with a personality disorder A service evaluation of a community mental health team

Prescribing medications for people with a personality disorder A service evaluation of a community mental health team Prescribing medications for people with a personality disorder A service evaluation of a community mental health team Dr Umama Khan, Consultant Psychiatrist Dr Venkatesh Ballagere, Specialist Registrar

More information

UnitedHealthcare Community (UHCCP) Louisiana Clinical Program Guidelines Record Supplemental Tool

UnitedHealthcare Community (UHCCP) Louisiana Clinical Program Guidelines Record Supplemental Tool December-18 UnitedHealthcare Community (UHCCP) Louisiana Clinical Program Guidelines Record Supplemental Tool Facility Name: Primary Dx: Member Gender: Member Age: Reviewer Name: Date of Facility Review:

More information

The place for treatments of associated neuropsychiatric and other symptoms

The place for treatments of associated neuropsychiatric and other symptoms The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public

More information

Manchester Self-Harm Project MaSH

Manchester Self-Harm Project MaSH MaSH Manchester Self-Harm Project MaSH 6 th Year Report 1 st September 2002 to 31 st August 2003 Jayne Cooper, Amy Johnston, Maria Healey, Iain Donaldson, Harriet Bickley, Navneet Kapur, Louis Appleby

More information

Young onset dementia service Doncaster

Young onset dementia service Doncaster Young onset dementia service Doncaster RDaSH Older People s Mental Health Services Introduction The following procedures and protocols will govern the operational working and function of the Doncaster

More information

2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative

2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative 2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative February 2014 Patient Population Measure spec for MU/PD generally follows NQF 0018 (used for HEDIS, PQRS, and MU) 1.6

More information

How do we sustain acceptance in societies with mandates: The situation in Germany

How do we sustain acceptance in societies with mandates: The situation in Germany How do we sustain acceptance in societies with mandates: The situation in Germany Sabine Reiter, Federal Ministry of Health Les Pensières, 25-27 September 2017 26.09.2017 Seite 1 Structure of german health

More information

Antipsychotic Prior Authorization Request

Antipsychotic Prior Authorization Request Antipsychotic Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth

More information

Alzheimer s Society. Consultation response. Our NHS care objectives: A draft mandate to the NHS Commissioning Board.

Alzheimer s Society. Consultation response. Our NHS care objectives: A draft mandate to the NHS Commissioning Board. Alzheimer s Society Our NHS care objectives: A draft mandate to the NHS Commissioning Board 26 September 2012 Delivering Dignity Securing dignity in care for older people in hospitals and care homes: A

More information

Number of records submitted: 14,750 Number of participants: Part 1 = 146 hospitals (120 trusts); Part 2 = 140 hospitals (119 trusts)

Number of records submitted: 14,750 Number of participants: Part 1 = 146 hospitals (120 trusts); Part 2 = 140 hospitals (119 trusts) British Thoracic Society Smoking Cessation Audit Report Smoking cessation policy and practice in NHS hospitals National Audit Period: 1 April 31 May 2016 Dr Sanjay Agrawal and Dr Zaheer Mangera Number

More information

Integrating Behavioral Health into Primary Care: Collaborative-Care Models

Integrating Behavioral Health into Primary Care: Collaborative-Care Models Integrating Behavioral Health into Primary Care: Collaborative-Care Models Presented at the National Health Policy Forum September 17 th, 2013 Marc Avery, MD Clinical Associate Professor Associate Director

More information

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral

More information

Connecticut Medicaid Emerging Adults

Connecticut Medicaid Emerging Adults Connecticut Medicaid Emerging Adults Child/Adolescent Quality, Access & Policy Committee April 18, 2018 Christopher Bory, PsyD, Beacon Health Options Agenda 1. National Context a. Gap in understanding

More information

VO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT)

VO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT) VO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT) Diagnostic Guidelines: Introduction: Electroconvulsive Therapy has been in continuous use for more than 60 years. The clinical literature

More information

Key Findings and Recommendations from the

Key Findings and Recommendations from the June 2014 Improving Community Health Through Policy Research Key Findings and Recommendations from the 2013 IPLA INSPECT Knowledge and Use Survey 2014 Center for Health Policy (14-H54) IU Richard M Fairbanks

More information

Mina Tadrous, Diana Martins, Zhan Yao, Kimberly Fernandes, Samantha Singh, Nikita Arora, David Juurlink, Muhammad Mamdani and Tara Gomes

Mina Tadrous, Diana Martins, Zhan Yao, Kimberly Fernandes, Samantha Singh, Nikita Arora, David Juurlink, Muhammad Mamdani and Tara Gomes Cognitive Enhancers Pharmacoepidemiology Report: FINAL CENSORED Report Mina Tadrous, Diana Martins, Zhan Yao, Kimberly Fernandes, Samantha Singh, Nikita Arora, David Juurlink, Muhammad Mamdani and Tara

More information

Research Protocol for REAP Bipolar Disorder (REAP-BD)

Research Protocol for REAP Bipolar Disorder (REAP-BD) Research Protocol for REAP Bipolar Disorder (REAP-BD) Summary REAP-BD survey will focus on the prescription patterns on bipolar disorder. Both inpatients and outpatients with bipolar disorder will be enrolled.

More information

Building Quality Into Outpatient Dementia Care For Mainers

Building Quality Into Outpatient Dementia Care For Mainers Building Quality Into Outpatient Dementia Care For Mainers Cliff Singer MD Chief, Geriatric Mental Health and Neuropsychiatry Principal Investigator, Alzheimer s Disease Clinical Research Program Acadia

More information

Executive Summary. The Royal Australasian College of Physicians July 2012 Page 1 of 5

Executive Summary. The Royal Australasian College of Physicians July 2012 Page 1 of 5 PBAC Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimer s disease Submission by The Royal Australasian College of Physicians July 2012 The Royal Australasian College of Physicians

More information

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components

More information

Bringing machine learning to the point of care to inform suicide prevention

Bringing machine learning to the point of care to inform suicide prevention Bringing machine learning to the point of care to inform suicide prevention Gregory Simon and Susan Shortreed Kaiser Permanente Washington Health Research Institute Don Mordecai The Permanente Medical

More information

Social inequalities in dementia care, cure, and research

Social inequalities in dementia care, cure, and research Online 4 April 2017 at the Journal of the American Geriatrics Society, doi: 10.1111/jgs.14893 AUTHOR POST-PRINT Social inequalities in dementia care, cure, and research Anja K. Leist, PEARL Institute for

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #283: Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

Urological cancers why we need to change. Stakeholder workshop 14 March 2013

Urological cancers why we need to change. Stakeholder workshop 14 March 2013 Urological cancers why we need to change Stakeholder workshop 14 March 2013 Introduction and welcome Today s event aims to cover: 1. Background, clinical evidence and London Cancer s recommendations Q&As

More information

Building a learning healthcare system for suicide prevention

Building a learning healthcare system for suicide prevention Building a learning healthcare system for suicide prevention Gregory Simon MD MPH Kaiser Permanente Washington Health Research Institute Mental Health Research Network Depression and Bipolar Support Alliance

More information

In addition, we have asked an English-editing service to edit the text, and you will find an English-edited version of the paper submitted as well.

In addition, we have asked an English-editing service to edit the text, and you will find an English-edited version of the paper submitted as well. Author s response to reviews Title: Resource Use and Disease Course in Dementia - Nursing Home (REDIC-NH): A Norwegian Cohort Study from Admission to a Nursing Home until Death. A description of study

More information

Lowering epilepsy-related treatment costs in the era of patient choice and value-based care

Lowering epilepsy-related treatment costs in the era of patient choice and value-based care Lowering epilepsy-related treatment costs in the era of patient choice and value-based care In-home EEG offers cost-effective, reliable alternative to traditional diagnostic services 01 Introduction One

More information

The STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018

The STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018 The STOP Measure Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018 AHIP s Safe, Transparent Opioid Prescribing (STOP) Initiative Methodology

More information

OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL

OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL Brian Fuehrlein, MD PhD VA Connecticut Healthcare System and Yale University I have no conflicts of interest or relevant financial

More information

TESTIMONY Of Pam Gehlmann Executive Director/ Assistant Regional Director Pinnacle Treatment Centers Alliance Medical Services-Johnstown

TESTIMONY Of Pam Gehlmann Executive Director/ Assistant Regional Director Pinnacle Treatment Centers Alliance Medical Services-Johnstown TESTIMONY Of Pam Gehlmann Executive Director/ Assistant Regional Director Pinnacle Treatment Centers Alliance Medical Services-Johnstown Center for Rural Pennsylvania On Confronting the Heroin Epidemic

More information

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017 Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic

More information

Evaluation of a Medicaid Psychotropic Drug Management Program in Utah

Evaluation of a Medicaid Psychotropic Drug Management Program in Utah Evaluation of a Medicaid Psychotropic Drug Management Program in Utah Dominick Esposito James M. Verdier 2008 SAMHSA/CMS Invitational Conference on Medicaid and Mental Health Service/Substance Abuse Treatment

More information

Asthma and COPD in Switzerland: Prevalence and direct medical costs according to health insurance claims data

Asthma and COPD in Switzerland: Prevalence and direct medical costs according to health insurance claims data WENNBERG INTERNATIONAL COLLABORATIVE SPRING POLICY MEETING 2018 Asthma and COPD in Switzerland: Prevalence and direct medical costs according to health insurance claims data Marion Schmidt 1, Roland Rapold

More information

Illinois CHIPRA Medical Home Project Baseline Results

Illinois CHIPRA Medical Home Project Baseline Results Illinois CHIPRA Medical Home Project Baseline Results On the National Committee for Quality Assurance Patient Centered Medical Home Self-Assessment June 25, 2012 Prepared by MetroPoint Research & Evaluation,

More information

Based on Medicare FFS Beneficiaries Assigned July 1, 2011 December 31, 2011

Based on Medicare FFS Beneficiaries Assigned July 1, 2011 December 31, 2011 July 2012 Multi-payer Advanced Primary Care Practice (MAPCP) Demonstration Medical Home Feedback Report Based on Medicare FFS Beneficiaries Assigned July 1, 2011 December 31, 2011 Practice Number Practice

More information

Taking Care: Child and Youth Mental Health PSYCHOSIS TREATMENT OPTIONS

Taking Care: Child and Youth Mental Health PSYCHOSIS TREATMENT OPTIONS Taking Care: Child and Youth Mental Health PSYCHOSIS TREATMENT OPTIONS Open Learning Agency 2004 TREATMENT OPTIONS Psychosis is highly treatable, especially if caught early. The prognosis for recovery

More information

NQF Behavioral Health Project Phase II Submitted Measures

NQF Behavioral Health Project Phase II Submitted Measures 0103 Major Depressive Disorder (MDD): Diagnostic Evaluation Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of MDD who met the DSM-IV criteria during the visit

More information

Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit

Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed

More information

Hospital Discharge Data

Hospital Discharge Data Hospital Discharge Data West Virginia Health Care Authority Hospitalization data were obtained from the West Virginia Health Care Authority s (WVHCA) hospital discharge database. Data are submitted by

More information

University of South Florida OCD, Anxiety, and Related Disorders Behavioral Treatment Program

University of South Florida OCD, Anxiety, and Related Disorders Behavioral Treatment Program OCD and Related Disorders Clinic Profile University of South Florida OCD, Anxiety, and Related Disorders Behavioral Treatment Program Clinic/Program Director: Adam B. Lewin, PhD, ABPP Name of Intake Coordinator:

More information

Coordinated Specialty Care: A New Approach to Addressing Emerging Serious Mental Illness in Young Adults

Coordinated Specialty Care: A New Approach to Addressing Emerging Serious Mental Illness in Young Adults Coordinated Specialty Care: A New Approach to Addressing Emerging Serious Mental Illness in Young Adults Rhonda Thissen, M.S.W. DBHDS Office of Adult Community Behavioral Health DBHDS Vision: A life of

More information

Cerebral Stimulant and ADHD Drugs Prior Authorization Request

Cerebral Stimulant and ADHD Drugs Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 Cerebral Stimulant and ADHD Drugs Prior Authorization

More information

The effect of continuity of ambulatory care on hospitalizations in patients with heart failure

The effect of continuity of ambulatory care on hospitalizations in patients with heart failure The effect of continuity of ambulatory care on hospitalizations in patients with heart failure DGGÖ 17.03.2014 Verena Vogt 1, Diana Kurch-Bek 2, Leonie Sundmacher 3 1 Fachgebiet Management im Gesundheitswesen,

More information

Dementia Benchmarking Indicators Definitions and Data Sources Manual

Dementia Benchmarking Indicators Definitions and Data Sources Manual Indicators Definitions and Data Sources Manual (September 2015) 1 Contents Page Number Dementia Indicators 3 Indicator Summary Tables 4 General Notes 22 Glossary 23 Appendix 1 Dementia Criteria 24 2 Indicators

More information

-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine

-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine -Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine An independent report Time for action 1 by Professor Sube Banerjee looked

More information

Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years

Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years 2004-2008 Laura Governale, Pharm.D., MBA Team Leader, Drug Utilization Data Analyst Hina Mehta, Pharm.D. Drug Utilization

More information

Antidepressant Prior Authorization Request

Antidepressant Prior Authorization Request Antidepressant Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth

More information

Worcestershire Dementia Strategy

Worcestershire Dementia Strategy Worcestershire Dementia Strategy An Easy Read Summary Introduction This is a plan about how we will support people with dementia, their families and carers in Worcestershire. This is called the Worcestershire

More information

Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines

Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding

More information

Depression Disease Navigation

Depression Disease Navigation Depression Disease Navigation The depression disease navigation program is designed to reach out to members who have been diagnosed with major depression disorder. This is accomplished by promoting treatment

More information

Alcohol Opiates Other:

Alcohol Opiates Other: Pages 1 and 2 must be completed in full for all referrals (incomplete forms will not be processed) Additional Required Information Form must be completed for all referrals Medication Clinic (Pg. 3), ECT

More information

CARE NEEDED: Improving the lives of people with dementia. Francesca Colombo Head of the OECD Health Division London, 12 June 2018

CARE NEEDED: Improving the lives of people with dementia. Francesca Colombo Head of the OECD Health Division London, 12 June 2018 CARE NEEDED: Improving the lives of people with dementia Francesca Colombo Head of the OECD Health Division London, 12 June 2018 Dementia affects million of people in OECD, and the numbers will continue

More information

LCA Mental Health & Psychological Support Mapping

LCA Mental Health & Psychological Support Mapping LCA Mental Health & Psychological Support Mapping November 2013 Contents 1 Introduction... 3 2 Method... 3 3 Results... 3 3.1 Information Centres... 3 3.2 Training and Education... 5 3.3 Level Two Supervision...

More information

Unmanaged Behavioral Health Puts Your Company At Risk. Presented by: Dr. Sam Mayhugh Integrated Behavioral Health

Unmanaged Behavioral Health Puts Your Company At Risk. Presented by: Dr. Sam Mayhugh Integrated Behavioral Health Unmanaged Behavioral Health Puts Your Company At Risk Presented by: Dr. Sam Mayhugh Integrated Behavioral Health Behavioral Health Management Webinar Overview History of BH management Prevalence of behavioral

More information

Anticonvulsant Prior Authorization Request

Anticonvulsant Prior Authorization Request Anticonvulsant Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth

More information

Mental Health Cardiff University

Mental Health Cardiff University Mental Health research @ Cardiff University Strong focus on integrated, multilevel mechanistic understanding based on inter-disciplinarity Driven by human genetics, aimed to deliver knowledge spanning

More information

DIGNITY IN DEMENTIA. G7 dementia legacy event Japan 6 th November 2014

DIGNITY IN DEMENTIA. G7 dementia legacy event Japan 6 th November 2014 G7 dementia legacy event Japan 6 th November 2014 DIGNITY IN DEMENTIA How better policy can improve the lives of people with dementia Mark Pearson Deputy Director Directorate for Employment, Labour and

More information

New Mexico. Prescribing and Dispensing Profile. Research current through November 2015.

New Mexico. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile New Mexico Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Response to Concerns of NQF Neurology Steering Committee

Response to Concerns of NQF Neurology Steering Committee November 30, 2012 6312 Old Keene Mill Court Springfield, VA 22152 Phone: 703-690-1987: www.pqaalliance.org Fax: 703-690-1756 To: National Quality Forum From: David Nau, PhD, RPh, CPHQ, FAPhA Senior Director,

More information

Mental Health Current Articles Bulletin - April 2017

Mental Health Current Articles Bulletin - April 2017 Library and Knowledge Services Mental Health Current Articles Bulletin - April 2017 Please see below for recent articles found in our print journal collection that may be of interest Alcohol and Substance

More information

The NYC Elder Abuse Center

The NYC Elder Abuse Center The NYC Elder Abuse Center Brooklyn Geriatric Mental Health and Medical Provider Survey You can also complete this survey online: http://www.surveymonkey.com/s/geriatricproviders PLEASE PRINT CLEARLY Preamble

More information

NHS RightCare Frailty Pathway An optimal frailty system

NHS RightCare Frailty Pathway An optimal frailty system NHS RightCare Frailty Pathway An optimal frailty system Martin Vernon National Clinical Director for Older People Adrian Hopper Consultant Physician & Frailty Pathway GiRFT Lead Alex Thompson Pathways

More information

Appendix K: Evidence review flow charts

Appendix K: Evidence review flow charts K.1 Dementia diagnosis K.1.1 Dementia diagnosis What are the most effective methods of primary assessment to decide whether a person with suspected dementia should be referred to a dementia service? What

More information

SADAG submission to the Competition Commission: Market Inquiry into the Private Healthcare Sector

SADAG submission to the Competition Commission: Market Inquiry into the Private Healthcare Sector THE SOUTH AFRICAN DEPRESSION AND ANXIETY GROUP NPO 013-085 Reg. No. 2000/025903/08 P O Box 652548 Benmore 2010 Tel: +27 11 234 4870 Fax: +27 11 234 8182 office@anxiety.org.za www.sadag.org SADAG submission

More information

IEHP UM Subcommittee Approved Authorization Guidelines Electroconvulsive Therapy- ECT

IEHP UM Subcommittee Approved Authorization Guidelines Electroconvulsive Therapy- ECT Electroconvulsive Therapy- ECT Policy: IEHP considers ECT medically necessary for members with the following disorders: 1. Unipolar and bipolar depression. 2. Bipolar mania. 3. Psychotic disorders including

More information

Access to Essential Medicines for MNS Disorders with the Greatest Burden: Focus on Depression, Psychosis and Epilepsy

Access to Essential Medicines for MNS Disorders with the Greatest Burden: Focus on Depression, Psychosis and Epilepsy Access to Essential Medicines for MNS Disorders with the Greatest Burden: Focus on Depression, Psychosis and Epilepsy Atalay Alem, MD, PhD Department of Psychiatry, School of Medicine, College of Health

More information

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There

More information

Performance Indicator Trending Report

Performance Indicator Trending Report MICHIGAN MISSION-BASED PERFORMANCE INDICATOR SYSTEM CMHSP Performance Indicator Trending Report FY 15 FY 17 updated August 217 Indicator 1: ACCESS-TIMELINESS/INPATIENT SCREENING: The percentage of persons

More information